| Sep 3 |
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
|
| Sep 2 |
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
|
| Aug 27 |
Peering Into Vaxcyte's Recent Short Interest
|
| Aug 6 |
Vaxcyte GAAP EPS of -$1.10 misses by $0.12
|
| Aug 6 |
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 31 |
Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?
|
| Jul 29 |
Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice
|
| Jul 2 |
Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX)
|
| Jul 2 |
Vaxcyte Appoints John Furey to Board of Directors
|
| May 24 |
Vaxcyte files for a mixed shelf offering
|
